Veradermics raised a lot of cash, then burned more of it.

In the six months ended June 30, operating cash flow fell from negative $21.2 million to negative $35.7 million. Cash itself climbed from $168.4 million to $319.3 million, but the increase came from selling equity, not from the business generating cash.

That distinction matters because the company also ended the period with 40.4 million diluted shares, up from 22.7 million in the comparable period. The balance sheet is larger. So is the share count that represents it.

The operating picture was less dramatic than the financing headline. Operating income was essentially unchanged at a loss of roughly $30 million, while net loss improved from $27.2 million to $23.5 million. Research and development spending fell 11% to $18.6 million, and stock compensation declined to $3.5 million.

Management says the remaining loss is concentrated in the company’s lead program, VDPHL01, along with the ordinary costs of being a public company. The report puts it this way:

"The net loss for the period was primarily driven by research and development spend related to VDPHL01, employee-related payroll and benefits costs, and professional fees related to operating as a public company."

Veradermics, 10-Q filed August 11, 2026

That is a narrower development plan than a company spreading money across several candidates, but it does not make the spending disappear. The company also said it paused work on VDMN and other programs to focus on VDPHL01, reducing manufacturing and clinical-trial costs tied to those candidates.

The cash increase has a similarly specific explanation. Veradermics disclosed that the period included $269.1 million from its initial public offering and $442.5 million from a follow-on offering and PIPE, compared with $8.4 million from its Series B financing in the prior year.

"The increase was primarily attributable to proceeds of $269.1 million from our initial public offering and $442.5 million from the follow-on offering and PIPE compared to proceeds of $8.4 million from the issuance of our Series B financing in the prior year."

Veradermics, 10-Q filed August 11, 2026

The plain-English version is less tidy than the cash balance: Veradermics bought time with new capital, while its operating cash needs increased. The filing does not provide a cash runway figure, and it does not explain the full deterioration in operating cash flow from the supplied figures.

The stock adds some market context without resolving the operating question. MANE closed at $110.78 on August 10, down 3.2% that day, after gaining 187.9% over six months. Equity financing is visible in the cash balance, but the 78% increase in diluted shares is impossible to ignore.

The company has described VDPHL01 as the center of its spending and paused other candidates around it. The unanswered question is simple: how long does the $319.3 million cash balance fund that concentrated development effort at this rate?